CoronaryAtlas logo
CoronaryAtlas
Apolipoprotein A-I
Pathway / Lipid retention & oxidation

Apolipoprotein A-I

APOA1protein

ApoA-I is the major HDL component mediating reverse cholesterol transport and endothelial protective effects; reduced levels indicate atherosclerotic burden.

Pathway placement
Cascade stepLipid retention & oxidation
Confidencehigh
RationaleHDL apolipoprotein; reverse cholesterol transport; atheroprotective; altered in ACS.
Also acts inSystemic / off-pathway
Druggability
DruggableYes
Known drugs / candidates0
Small-molecule tractableYes
Antibody tractableYes
EnsemblENSG00000118137

Type I vs Type II discrimination

ScoresShared / rises in both
R — rupture / Type-I
67
C — confounder / Type-II
67
A — assay feasibility
84
E — evidence strength
62
T1DI (composite)
26
Specificity differential (R−C)0
Confounder panel (Type-II drivers)
1sepsis / systemic inflammationn/a
2anemia / acute blood lossn/a
3hypovolemia / dehydrationmag 2
4tachyarrhythmian/a
5hypoxemia / respiratory failuren/a
6hypertensive emergencyn/a
7high-demand / peri-operative stressmag 2
Coverage: 2/7 confounders with evidence
Tier: deep-scored (abstract-extracted) · 6 supporting references. See the discrimination table for all markers.

Assay & specimen

Validated clinical assay
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST)
Method / principle
Immunoturbidimetric/nephelometric
Reagent / substrate
Anti-apoA-I antibody-latex
Platform
Automated analyzer
Turnaround · availability
Routine · Universal

Literature evidence(30)

Clinical trials(1)